We provide you with 20 years of free, institutional-grade data for IMMP stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of IMMP. Explore the full financial landscape of IMMP stock.
| Reported Date | CIK | Ticker | Type |
|---|
Immutep Limited(NASDAQ:IMMP) 
Immutep Limited, a biotech company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its principal product candidate is IMP321, also known as ?eftilagimod alpha' or ?efti...
The information provided in this report about IMMP stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.